Publications by authors named "Colton Wright"
Background: The relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral dynamics during acute infection and the development of long coronavirus disease 2019 (COVID-19), or "long COVID," is largely unknown.
Methods: Between October 2021 and February 2022, 7361 people not known to have COVID-19 self-collected nasal swab samples for SARS-CoV-2 reverse-transcription polymerase chain reaction testing every 24-48 hours for 10-14 days. Participants whose first known SARS-CoV-2 infection was detected were surveyed for long COVID in August 2023.
Shortly after the first case of SARS-CoV-2 was diagnosed a public health emergency (PHE) was declared and a multi-agency response was initiated within the US federal government to create and propagate testing capacity. As part of this response, an unprecedented program designated Rapid Acceleration of Diagnostics (RADx) Tech was established by the National Institutes of Health (NIH) to facilitate the development of point-of-care tests for the COVID-19. The RADx Tech Clinical Studies Core (CSC), located at the University of Massachusetts Chan Medical School (UMass Chan), with partnering academic, private, and non-governmental organizations around the country, was tasked with developing clinical studies to support this work.
View Article and Find Full Text PDFIntroduction: The relationship between SARS-CoV-2 viral dynamics during acute infection and the development of long COVID is largely unknown.
Methods: A total of 7361 asymptomatic community-dwelling people enrolled in the Test Us at Home parent study between October 2021 and February 2022. Participants self-collected anterior nasal swabs for SARS-CoV-2 RT-PCR testing every 24-48 hours for 10-14 days, regardless of symptom or infection status.
Article Synopsis
- The study analyzed the effectiveness of rapid and PCR tests for detecting SARS-CoV-2 after symptom onset and exposure among various populations in the U.S. between October 2021 and February 2022.
- Findings showed that test positivity was highest two days after symptoms began and six days after exposure, with Ag-RDTs detecting around 84.9% of infections within four days of symptoms.
- Results indicated no significant differences in test performance based on vaccination status, age, sex, or virus variant, but asymptomatic individuals had lower Ag-RDT positivity rates compared to those with symptoms.
Background: The performance of rapid antigen tests (Ag-RDTs) for screening asymptomatic and symptomatic persons for SARS-CoV-2 is not well established.
Objective: To evaluate the performance of Ag-RDTs for detection of SARS-CoV-2 among symptomatic and asymptomatic participants.
Design: This prospective cohort study enrolled participants between October 2021 and January 2022.
Background: The performance of rapid antigen tests for SARS-CoV-2 (Ag-RDT) in temporal relation to symptom onset or exposure is unknown, as is the impact of vaccination on this relationship.
Objective: To evaluate the performance of Ag-RDT compared with RT-PCR based on day after symptom onset or exposure in order to decide on 'when to test'.
Design Setting And Participants: The Test Us at Home study was a longitudinal cohort study that enrolled participants over 2 years old across the United States between October 18, 2021 and February 4, 2022.
Background: It is important to document the performance of rapid antigen tests (Ag-RDTs) in detecting SARS-CoV-2 variants.
Objective: To compare the performance of Ag-RDTs in detecting the Delta (B.1.
Background: Performance of rapid antigen tests for SARS-CoV-2 (Ag-RDT) varies over the course of an infection, and their performance in screening for SARS-CoV-2 is not well established. We aimed to evaluate performance of Ag-RDT for detection of SARS-CoV-2 for symptomatic and asymptomatic participants.
Methods: Participants >2 years old across the United States enrolled in the study between October 2021 and February 2022.
Article Synopsis
- * Out of 5,506 eligible participants, 153 tested positive via RT-PCR (61 for Delta, 92 for Omicron), with only 23.5% testing Ag-RDT positive on the same day and 54.9% within 48 hours, showing no significant difference in sensitivity between the two variants.
- * The findings suggest that while Ag-RDT performance is slightly better for Omicron, the differences are not statistically significant, and a subset of participants remained Ag-RDT negative despite testing positive